
Opinion|Videos|January 8, 2024
Final iDFS Analysis from NATALEE in HR+/HER2- Early Breast Cancer
Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
4
Lung Cancer News Roundup: June 2026
5












































